A ray of light recently pierced the gloom surrounding Basilea Pharmaceutica AG's program for its cephalosporin antibiotic ceftobiprole (Zevtera), which is in development for complicated skin and soft tissue infections. (BioWorld International)

U.S. Stem Cell Research Policy too Cumbersome, Critic Charges

By Nuala Moran

Wednesday, February 24, 2010

Buy Reprint

No Abstract

New Class of Antibiotics Poised to Begin Clinical Trial Testing

By Sharon Kingman

Wednesday, February 24, 2010

Buy Reprint

No Abstract

NewCo News: New Money Scarce, so ITS Founders Chip in $13.4M

By Nuala Moran

Wednesday, February 24, 2010

Buy Reprint

No Abstract

BioWorld

Store

Others

BioWorld-International-2010-02-24

Remodulin Price Hike to Offset Tyvaso's Four-Year Delay in EU

DeveloGen Gets JDRF Grant for Work on Beta Cell Survival

As Labopharm Prepares for Oleptro Launch, it Seeks $20M

Other News To Note

Basilea: Ceftobiprole Custody in Post-EMA Divorce from J&J

U.S. Stem Cell Research Policy too Cumbersome, Critic Charges

New Class of Antibiotics Poised to Begin Clinical Trial Testing

NewCo News: New Money Scarce, so ITS Founders Chip in $13.4M

Explore BioWorld.com

BioWorld

Store

Others

Login to Your Account

BioWorld

Store

Others

BioWorld-International-2010-02-24

Explore BioWorld.com

BioWorld

Store

Others